EU Proposes Measures to Boost Health Sector Innovation and Resilience

Key highlights
  • The Biotech Act aims to mobilize €10 billion investment for Europe's biotech sector.
  • Cardiovascular diseases cost the EU economy €282 billion annually.
  • Medical device reforms could save €3.3 billion per year, including €2.4 billion in administrative savings.
  • The Safe Hearts Plan sets clear goals for cardiovascular health improvements by 2035.

Overview

The European Commission has proposed measures to enhance the EU health sector's innovation, competitiveness, and resilience. This includes the Biotech Act, Safe Hearts Plan, and medical device reforms.

Biotech Act

The Biotech Act aims to boost Europe's biotechnology sector, which contributes €40 billion to the economy and employs over 900,000 people. It addresses funding gaps and regulatory barriers, promoting research and production within Europe. The Act will explore new funding methods and accelerate clinical trials, aiming to establish a leading health biotech industry.

Safe Hearts Plan

Cardiovascular diseases, the leading cause of premature death in the EU, cost the economy €282 billion annually. The Safe Hearts Plan is the first comprehensive EU approach to tackle this issue, focusing on prevention, detection, and treatment. It aims to reduce health inequalities and improve access to care, with goals set for 2035.

Medical Devices

The EU's medical device sector, valued at €170 billion, faces regulatory challenges. Proposed reforms aim to simplify rules, support digitalization, and ensure patient safety. The European Medicines Agency will play a stronger role in coordination and monitoring shortages. These changes could lead to €3.3 billion in annual savings, including €2.4 billion in administrative costs.

Next Steps

The legislative proposals will be submitted to the European Parliament and the Council for adoption. Implementation of the Safe Hearts Plan will begin in collaboration with Member States.

Source: EIB

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

18 September 2026
Novo Nordisk’s Sogroya recommended by EMA CHMP for idiopathic short stature in children

Once-weekly somapacitan (Sogroya) receives CHMP positive opinion for children with idiopathic short stature; European Commission decision expected later this year.

10 September 2026
Roche's Enspryng granted FDA Priority Review for MOGAD

FDA accepted the application for satralizumab for adult and adolescent MOGAD and granted Priority Review with a decision due 10 Jan 2027; EMA validated the MAA, EC decision expected Q3 2027.

9 September 2026
Genentech: FDA grants Priority Review for Enspryng in MOGAD

Priority Review follows Phase III METEOROID showing 68% relapse risk reduction; FDA decision expected Jan 10, 2027; EMA validated the MOGAD filing with EC decision due Q3 2027.

12 December 2025
Merck's WINREVAIR™ Gains EU CHMP Support for Broader PAH Use

EU CHMP backs expanded WINREVAIR™ use for PAH, covering WHO FC II-IV. Decision by European Commission expected Q1 2026.